The Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA) revealed that the incidence of ovarian cancer is high in patients with germline BRCA mutation in the OCCR in about 30,000 BRCA mutant carriers in 33 countries around the world [50]. The gene discussed is BRCA1; the disease is ovarian cancer.